{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:48:52Z","timestamp":1758815332784},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1097\/mop.0000000000000228","type":"journal-article","created":{"date-parts":[[2015,4,17]],"date-time":"2015-04-17T08:10:31Z","timestamp":1429258231000},"page":"405-417","source":"Crossref","is-referenced-by-count":8,"title":["Immunizing adolescents"],"prefix":"10.1097","volume":"27","author":[{"given":"Rebecca J.","family":"Schneyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherina","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Bocchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-23-20210206","first-page":"625","article-title":"Immunization Services Division, National Center for Immunization and Respiratory Diseases; Centers for Disease Control and Prevention (CDC). National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2013.","volume":"63","author":"Elam-Evans","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R4-23-20210206","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/MOP.0000000000000139","article-title":"Pertussis: still a cause of death, seven decades into vaccination.","volume":"26","author":"Jakinovich","year":"2014","journal-title":"Curr Opin Pediatr"},{"key":"R5-23-20210206","first-page":"13","article-title":"Prevention, (CDC)Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010.","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R6-23-20210206","first-page":"131","article-title":"Prevention, (CDC)Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women - Advisory Committee on Immunization Practices (ACIP), 2012.","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R7-23-20210206","doi-asserted-by":"crossref","first-page":"e1716","DOI":"10.1542\/peds.2012-3836","article-title":"Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers.","volume":"131","author":"Klein","year":"2013","journal-title":"Pediatrics"},{"key":"R8-23-20210206","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMc1212006","article-title":"Priming with whole-cell versus acellular and pertussis vaccine.","volume":"368","author":"Liko","year":"2013","journal-title":"N Engl J Med"},{"key":"R9-23-20210206","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/infdis\/jiu322","article-title":"Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand.","volume":"210","author":"Koepke","year":"2014","journal-title":"J Infect Dis"},{"key":"R10-23-20210206","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/cid\/ciu273","article-title":"Pertussis vaccine performance in an epidemic year Oregon, 2012.","volume":"59","author":"Liko","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R11-23-20210206","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/cid\/ciu156","article-title":"Vaccinated children and adolescents with pertussis infections experience reduced illness severity and duration, Oregon, 20102012.","volume":"58","author":"Barlow","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R12-23-20210206","doi-asserted-by":"crossref","first-page":"e1149","DOI":"10.1542\/peds.2013-1747","article-title":"Infant hospitalizations for pertussis before and after Tdap recommendations for adolescents.","volume":"132","author":"Auger","year":"2013","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"R13-23-20210206","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1093\/infdis\/jit531","article-title":"Possible options for new pertussis vaccines.","volume":"209","author":"Meade","year":"2014","journal-title":"J Infect Dis"},{"key":"R14-23-20210206","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1016\/j.vaccine.2014.08.038","article-title":"The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels - a prospective study.","volume":"32","author":"Abu Raya","year":"2014","journal-title":"Vaccine"},{"key":"R15-23-20210206","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1001\/jama.2014.3633","article-title":"Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial.","volume":"311","author":"Munoz","year":"2014","journal-title":"JAMA"},{"key":"R16-23-20210206","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/jama.2014.14825","article-title":"Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes.","volume":"312","author":"Kharbanda","year":"2014","journal-title":"JAMA"},{"key":"R17-23-20210206","doi-asserted-by":"crossref","first-page":"g4219","DOI":"10.1136\/bmj.g4219","article-title":"Safety of pertussis vaccination in pregnant women in UK: observational study.","volume":"349","author":"Donegan","year":"2014","journal-title":"BMJ"},{"key":"R18-23-20210206","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S0140-6736(14)60686-3","article-title":"Effectiveness of maternal pertussis vaccination in England: an observational study.","volume":"384","author":"Amirthalingam","year":"2014","journal-title":"Lancet"},{"key":"R19-23-20210206","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/cid\/ciu821","article-title":"A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 20122013.","volume":"60","author":"Dabrera","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R20-23-20210206","doi-asserted-by":"crossref","first-page":"e1748","DOI":"10.1542\/peds.2012-3144","article-title":"Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis.","volume":"131","author":"Terranella","year":"2013","journal-title":"Pediatrics"},{"key":"R21-23-20210206","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/INF.0000000000000486","article-title":"Evaluation of the impact of a Pertussis Cocooning Program on infant pertussis infection.","volume":"34","author":"Healy","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"RR-2","key":"R23-23-20210206","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC)Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"R30-23-20210206","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1331\/JAPhA.2014.14512","article-title":"Meningococcal serogroup B outbreaks and use of 4CMenB vaccine.","volume":"54","author":"Rose","year":"2014","journal-title":"J Am Pharm Assoc"},{"key":"R33-23-20210206","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b3 randomised, observer-blind, placebo-controlled study.","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"R34-23-20210206","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine.","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"R35-23-20210206","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"R36-23-20210206","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"RR-05","key":"R39-23-20210206","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm Rep"},{"key":"R40-23-20210206","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/OLQ.0b013e318286bb53","article-title":"Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008.","volume":"40","author":"Satterwhite","year":"2013","journal-title":"Sex Transm Dis"},{"key":"R41-23-20210206","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.","volume":"11","author":"deSanjose S, Quint","year":"2010","journal-title":"Lancet Oncol"},{"issue":"Suppl 3","key":"R42-23-20210206","first-page":"S335","article-title":"Chapter 4: burden and management of noncancerous HPV-related conditions: HPV-611 disease.","volume":"24","author":"Lacey","year":"2006","journal-title":"Vaccine"},{"key":"R44-23-20210206","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMe1415742","article-title":"HPV Coverage.","volume":"372","author":"Schuchat","year":"2015","journal-title":"N Engl J Med"},{"key":"R47-23-20210206","doi-asserted-by":"crossref","first-page":"e657","DOI":"10.1542\/peds.2013-4144","article-title":"Long-term study of a quadrivalent human papillomavirus vaccine.","volume":"134","author":"Ferris","year":"2014","journal-title":"Pediatrics"},{"key":"R48-23-20210206","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/jit192","article-title":"Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 20032010.","volume":"208","author":"Markowitz","year":"2013","journal-title":"J Infect Dis"},{"key":"R49-23-20210206","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.vaccine.2012.10.092","article-title":"Impact of human papillomavirus (HPV) vaccination on HPV 1618-related prevalence in precancerous cervical lesions.","volume":"31","author":"Powell","year":"2012","journal-title":"Vaccine"},{"key":"R50-23-20210206","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2334-13-140","article-title":"Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program.","volume":"13","author":"Ali","year":"2013","journal-title":"BMC Infect Dis"},{"key":"R51-23-20210206","doi-asserted-by":"crossref","first-page":"e105967","DOI":"10.1371\/journal.pone.0105967","article-title":"Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: results from a nationally representative cross-sectional general practice study.","volume":"9","author":"Harrison","year":"2014","journal-title":"PLoS One"},{"key":"R53-23-20210206","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1038\/bjc.2014.198","article-title":"Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 1618 and closely related HPV types.","volume":"110","author":"Kavanagh","year":"2014","journal-title":"Br J Cancer"},{"key":"R54-23-20210206","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/bjc.2014.479","article-title":"Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland.","volume":"111","author":"Pollock","year":"2014","journal-title":"Br J Cancer"},{"key":"R55-23-20210206","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.vaccine.2014.12.021","article-title":"Age at HPV vaccine initiation and completion among US adolescent girls: trend from 2008 to 2012.","volume":"33","author":"Rahman","year":"2015","journal-title":"Vaccine"},{"key":"R57-23-20210206","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2105\/AJPH.2012.301189","article-title":"Longitudinal predictors of human papillomavirus vaccination among a national sample of adolescent males.","volume":"103","author":"Reiter","year":"2013","journal-title":"Am J Public Health"},{"key":"R58-23-20210206","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1542\/peds.2014-0442","article-title":"Missed opportunities for HPV vaccination in adolescent girls: a qualitative study.","volume":"134","author":"Perkins","year":"2014","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"R59-23-20210206","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.ygyno.2014.01.046","article-title":"HPV vaccine use among African American girls: qualitative formative research using a participatory social marketing approach.","volume":"132","author":"Hull","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R61-23-20210206","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.4161\/hv.28022","article-title":"Immune response to the HPV-1618 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study.","volume":"10","author":"Romanowski","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R62-23-20210206","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"key":"R63-23-20210206","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jama.2011.407","article-title":"Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.","volume":"305","author":"Neuzil","year":"2011","journal-title":"JAMA"},{"key":"R64-23-20210206","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/infdis\/jit363","article-title":"Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.","volume":"208","author":"LaMontagne","year":"2013","journal-title":"J Infect Dis"},{"key":"R68-23-20210206","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.canep.2014.09.003","article-title":"Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China).","volume":"38","author":"Serrano","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"R71-23-20210206","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"R72-23-20210206","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.acap.2013.01.002","article-title":"A randomized trial of the effect of centralized reminderrecall on immunizations and preventive care visits for adolescents.","volume":"13","author":"Szilagyi","year":"2013","journal-title":"Acad Pediatr"},{"key":"R73-23-20210206","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.pedhc.2013.09.001","article-title":"Increasing HPV vaccination series completion rates via text message reminders.","volume":"28","author":"Matheson","year":"2014","journal-title":"J Pediatr Healthcare"},{"key":"R74-23-20210206","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1542\/peds.2014-2475","article-title":"Text message reminders for second dose of influenza vaccine: a randomized controlled trial.","volume":"135","author":"Stockwell","year":"2015","journal-title":"Pediatrics"},{"key":"R75-23-20210206","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1542\/peds.2013-4257","article-title":"Increasing provision of adolescent vaccines in primary care: a randomized controlled trial.","volume":"134","author":"Gilkey","year":"2014","journal-title":"Pediatrics"},{"key":"R76-23-20210206","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1016\/j.vaccine.2014.05.044","article-title":"Intervention effects from a social marketing campaign to promote HPV vaccination in preteen boys.","volume":"32","author":"Cates","year":"2014","journal-title":"Vaccine"},{"key":"R78-23-20210206","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jadohealth.2013.05.009","article-title":"Missed opportunities for adolescent vaccination, 2006-2011.","volume":"53","author":"Wong","year":"2013","journal-title":"J Adolesc Health"},{"key":"R79-23-20210206","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1542\/hpeds.2014-0027","article-title":"A pilot program to improve vaccination status for hospitalized children.","volume":"5","author":"Pahud","year":"2015","journal-title":"Hosp Pediatr"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000000228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:29:44Z","timestamp":1620962984000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201506000-00023"}},"subtitle":["a selected review of recent literature and US recommendations"],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000228","relation":{},"ISSN":["1040-8703"],"issn-type":[{"value":"1040-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}